| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
VECTORMUNE® FP MG Vaccine
Record information and status
Record ID
105419
Status
Published
Date of creation
2014-02-27 18:43 UTC (gutemberg.sousa@mcti.gov.br)
Date of publication
2014-03-14 17:28 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
VECTORMUNE® FP MG Vaccine
Transformation event
FP MG
Developer(s)
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saúde Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulínia - SP
Paulínia, São Paulo
Brazil, 13140-000
Phone:551938337700
Fax:55193833-7722
Email:alexisgoux@ceva.com
Url:CEVA
Description
VECTORMUNE® FP MG is a genetically engineered live virus vaccine for the vaccination of chickens as an aid in the prevention of fowl pox and Mycoplasma gallisepticum. The fowl pox vaccine has been genetically engineered to contain and express key protective Mycoplasma gallisepticum bacterial antigens.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Fowlpox virus - FOWPV
Characteristics of the transformation process
Vector
pUC18
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
mgc3 gene - Mycoplasma gallisepticum - MG, MYCGL
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
MG 40k antigen gene - Mycoplasma gallisepticum - MG, MYCGL
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
A 3kb Hpal-Spel fragment of the FPV genome was inserted into a EcoR1-HindIII site of a pUC18 vector. The homologous recombination site may be interrupting a possible open reading frame but is thought to be non-essential for viral replication and has no known function in the FPV.

A 175bp EcoRV fragment of the FPV genome was removed from this construct and replaced with the MG 40K and mcg3 coding sequences.

Regulatory sequences were also inserted into the vector. The MG 40K and mcg3 genes were each coupled with a synthetic Ps promoter, which emulates the consensus early/late promoter of poxvirus. A termination sequence derived from the gB gene of the Marek Disease Virus was also inserted into the pUC18 vector.

Furthermore, a MDV gB transit signal sequence was added to the 3' terminus of the of MG 40K and mcg3 coding sequences to ensure localisation  to the cell membrane.

This construct and the attenuated parental FPV strain were co-transformed into chicken embryo fibroblasts (CEF) and incubated under conditions that favour homologous recombination.

After transfection, viral particles were cultivated from the chicken embryo fibroblasts and assayed for expression of MG 40K and mcg3 proteins. Plaques expressing MG 40K and mcg3 proteins were isolated and selected until the pure recombined virus was obtained.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine

Records referencing this document (1)
IDDescription
1record(s) found
Country's Decision or any other Communication1 record